🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

79 results for “NEUROCRINE BIOSCIENCES INC” Clear

  1. Chronocort®

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    5 trials

  2. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    4 trials

  3. Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  4. Hydrocortisone

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    2 trials

  5. Identical to NBI-1065845 tablets without active drug, NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  6. Indiplon

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  7. Infacort®

    NEUROCRINE BIOSCIENCES INC

    Adrenal Insufficiency

    phase 3 small molecule completed

    4 trials

  8. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  9. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  10. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  12. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  13. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  14. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  15. NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  16. NBI-34060

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  17. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  18. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    6 trials

  19. Placebo

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  20. Placebo

    NEUROCRINE BIOSCIENCES INC

    Dyskinesia

    phase 3 small molecule completed

    1 trial

  21. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Chorea, Huntington

    phase 3 small molecule active

    3 trials

  22. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    2 trials

  23. Valbenazine, Valbenazine, Placebo for valbenazine capsules

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  24. Chronocort

    NEUROCRINE BIOSCIENCES INC

    Primary Adrenal Insufficiency

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources